JP2023548368A - 複素環式メタノン化合物及びそのアザビシクロ中間体の製造方法 - Google Patents

複素環式メタノン化合物及びそのアザビシクロ中間体の製造方法 Download PDF

Info

Publication number
JP2023548368A
JP2023548368A JP2023526903A JP2023526903A JP2023548368A JP 2023548368 A JP2023548368 A JP 2023548368A JP 2023526903 A JP2023526903 A JP 2023526903A JP 2023526903 A JP2023526903 A JP 2023526903A JP 2023548368 A JP2023548368 A JP 2023548368A
Authority
JP
Japan
Prior art keywords
compound
formula
group
reaction
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548368A5 (https=
Inventor
グルーゲル，クリスチャン
Original Assignee
アクチノゲン メディカル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904060A external-priority patent/AU2020904060A0/en
Application filed by アクチノゲン メディカル リミテッド filed Critical アクチノゲン メディカル リミテッド
Publication of JP2023548368A publication Critical patent/JP2023548368A/ja
Publication of JP2023548368A5 publication Critical patent/JP2023548368A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00—Grignard reactions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023526903A 2020-11-06 2021-11-05 複素環式メタノン化合物及びそのアザビシクロ中間体の製造方法 Pending JP2023548368A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904060A AU2020904060A0 (en) 2020-11-06 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
AU2020904060 2020-11-06
PCT/AU2021/051310 WO2022094668A1 (en) 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Publications (2)

Publication Number Publication Date
JP2023548368A true JP2023548368A (ja) 2023-11-16
JP2023548368A5 JP2023548368A5 (https=) 2024-11-07

Family

ID=81458249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526903A Pending JP2023548368A (ja) 2020-11-06 2021-11-05 複素環式メタノン化合物及びそのアザビシクロ中間体の製造方法

Country Status (11)

Country Link
US (1) US20230416243A1 (https=)
EP (1) EP4240740A4 (https=)
JP (1) JP2023548368A (https=)
KR (1) KR20230154789A (https=)
CN (1) CN116981461A (https=)
AU (1) AU2021374232A1 (https=)
CA (1) CA3196642A1 (https=)
CL (1) CL2023001300A1 (https=)
IL (1) IL302671A (https=)
MX (1) MX2023004940A (https=)
WO (1) WO2022094668A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026509196A (ja) * 2023-03-02 2026-03-17 アクチノゲン メディカル リミテッド アザ二環式ヘテロアリール化合物を調製するための流動化学プロセス
WO2025073002A1 (en) * 2023-10-03 2025-04-10 Actinogen Medical Limited Tablet formulation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518799A (ja) * 2004-01-20 2007-07-12 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性モジュレーターとしての２，６−二置換ピペリジン
JP2009528371A (ja) * 2006-03-01 2009-08-06 セラヴァンス， インコーポレーテッド ミューオピオイド受容体拮抗剤としての８−アザビシクロ［３．２．１］オクタン化合物
WO2011090935A1 (en) * 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
JP2012506405A (ja) * 2008-10-23 2012-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ノルトロパンの尿素誘導体、該化合物を含有する医薬及びその使用
JP2013504613A (ja) * 2009-09-16 2013-02-07 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
JP2013527162A (ja) * 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2366058T3 (es) * 2006-03-01 2011-10-14 Theravance, Inc. Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu.
KR101445012B1 (ko) * 2009-12-17 2014-09-26 머크 샤프 앤드 돔 코포레이션 Ｓｙｋ 억제제로서의 아미노피리미딘

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007518799A (ja) * 2004-01-20 2007-07-12 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性モジュレーターとしての２，６−二置換ピペリジン
JP2009528371A (ja) * 2006-03-01 2009-08-06 セラヴァンス， インコーポレーテッド ミューオピオイド受容体拮抗剤としての８−アザビシクロ［３．２．１］オクタン化合物
JP2012506405A (ja) * 2008-10-23 2012-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ノルトロパンの尿素誘導体、該化合物を含有する医薬及びその使用
JP2013504613A (ja) * 2009-09-16 2013-02-07 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
WO2011090935A1 (en) * 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
JP2013527162A (ja) * 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACTA CHIMICA ACADEMIAE SCIENTIARUM HUNGARICAE, vol. 68(3), JPN6025040646, 1971, pages 253 - 9, ISSN: 0005703197 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 51(19), JPN6025040647, 2008, pages 6095 - 6109, ISSN: 0005703196 *

Also Published As

Publication number Publication date
US20230416243A1 (en) 2023-12-28
WO2022094668A1 (en) 2022-05-12
IL302671A (en) 2023-07-01
MX2023004940A (es) 2023-09-12
CN116981461A (zh) 2023-10-31
CL2023001300A1 (es) 2024-01-05
AU2021374232A1 (en) 2023-06-08
EP4240740A4 (en) 2024-12-11
KR20230154789A (ko) 2023-11-09
CA3196642A1 (en) 2022-05-12
EP4240740A1 (en) 2023-09-13
AU2021374232A9 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
TWI658042B (zh) 雜環化合物的合成
TW202332434A (zh) 可用作抗癌劑的吡唑基衍生物之合成方法
CN106946917A (zh) 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
JP2023548368A (ja) 複素環式メタノン化合物及びそのアザビシクロ中間体の製造方法
US8680332B2 (en) Disubstituted-aminodifluorosulfinium salts, process for preparing same and method of use as deoxofluorination reagents
JP7804068B2 (ja) 合成方法及び中間体
TWI812679B (zh) 製備可溶性鳥苷酸環化酶刺激劑之方法
WO2014081024A1 (ja) ５－置換－２－フェニルアミノ－ベンズアミド類の製造方法
CA3215792A1 (en) Processes for the synthesis of valbenazine
EP1824823A1 (en) Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
CA3268617A1 (en) Synthesis methods and intermediates
CN110573521B (zh) 4’-硫代核苷的新型化合物的制备方法和此制备方法中的中间体
WO2013140331A1 (en) New 1, 2, 4-oxadiazol derivatives, process for their preparation and use thereof as intermediates in the preparation of indolic alkaloids
WO2023064991A1 (en) Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereof
WO2025240628A1 (en) Processes for preparing a pkc inhibitor
IL325043A (en) Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
CN117736221A (zh) 瑞卢戈利中间体化合物及瑞卢戈利的制备方法
CN119954778A (zh) 一种来那卡帕韦钠及其系列中间体化合物的合成方法
JP2011526257A (ja) Ｎ−フェニル−ｎ−（４−ピペリジニル）アミド塩の製造方法
HK1257427A1 (zh) 制备2-吡唑并[1，5-a]吡嗪-2-基吡啶并[1，2-a]嘧啶-4-酮的方法
HK1257427B (en) A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
HK1172844B (en) Synthesis of a neurostimulative piperazine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203